July 2016 in “Reumatología Clínica (English Edition)” This review discusses the wide range of physiologic skin changes during pregnancy and highlights less frequently recognized changes, based on literature from the past decade, without reporting new clinical results.
January 2017 in “Springer eBooks” The document explains various skin conditions and their treatments.
16 citations
,
September 2020 in “British journal of dermatology/British journal of dermatology, Supplement” This review explores the role of neutrophil recruitment in the inflammation seen in hidradenitis suppurativa and emphasizes potential therapeutic targets within these pathways, but it reports no new clinical results.
3 citations
,
January 2010 in “Elsevier eBooks” The document describes various skin conditions, their features, and treatments but lacks detailed study size information.
December 2020 in “The journal of investigative dermatology/Journal of investigative dermatology” This study suggests that IL-1β may play a role in inflammatory signaling pathways in papulopustular rosacea, contributing to its pathogenesis.
July 2003 in “Journal of Cutaneous Medicine and Surgery” The document concludes that various treatments for skin conditions are effective, but some require further research, and certain factors like gender and lifestyle can influence disease outcomes.
March 2024 in “International Journal of Rheumatic Diseases” This case report describes successful wound healing in a patient with chronic gout and tophaceous ulcers following platelet-rich plasma therapy, highlighting its potential effectiveness in treating non-healing wounds.
66 citations
,
March 2018 in “British journal of dermatology/British journal of dermatology, Supplement” This article reviews the role of perifollicular regulatory T cells in maintaining hair follicle integrity in the context of hidradenitis suppurativa and calls attention to inflammatory mechanisms without reporting new clinical results.
1 citations
,
January 2017 in “Expert opinion on orphan drugs” This study reviews current systemic treatments for hidradenitis suppurativa, highlighting traditional methods and new options like biological agents, and suggests that pharmacological therapies show promise, particularly for non-advanced cases, despite the disease's complex etiology involving factors such as genetics and inflammation.
July 2026 in “Clinical Cosmetic and Investigational Dermatology” This review highlights advancements in drug delivery systems for treating psoriasis and atopic dermatitis, focusing on their ability to enhance transdermal drug efficacy and safety by overcoming skin barriers and enabling precise, on-demand drug release at target sites.
April 2020 in “The journal of investigative dermatology/Journal of investigative dermatology” This source reports that a study by Liu et al. analyzed genetic factors influencing adalimumab response in hidradenitis suppurativa, finding a specific genetic variant (SNP rs59532114) associated with an inadequate response to the treatment due to increased abscess and inflammatory nodule counts.
2 citations
,
March 2016 in “Obstetrics and Gynecology Clinics of North America” This article reviews common dermatologic conditions seen in primary care, such as acne and skin cancer, but reports no new findings.
11 citations
,
June 2024 in “Clinical ophthalmology” This study highlights that Demodex mites, commonly found on human skin, can cause significant eye and skin issues such as blepharitis, rosacea, and dermatitis when present in abnormally high densities, underscoring the need for targeted management strategies.
3 citations
,
August 2023 in “World Journal of Biology and Biotechnology” This research underscores the critical role of the human microbiome in health, highlighting potential therapeutic benefits of interventions like fecal microbiota transplantation and probiotics for conditions linked to microbiome dysbiosis, such as metabolic disorders and inflammatory diseases.
This study with zebrafish found that inherited personality traits significantly influence the response to social stress, showing that individuals with certain coping styles were more vulnerable to health impairments, such as increased gut inflammation, than their social ranking alone would suggest.
112 citations
,
July 2008 in “Dermatologic Therapy” This review outlines the diagnosis and management of folliculitis decalvans, an inflammatory scalp disorder, and highlights Staphylococcus aureus and immune response deficiencies as key factors in its development.
1 citations
,
January 2021 in “Journal of the Dermatology Nurses’ Association” This article discusses various dermatological topics from the 2020 Dermatology Nurses' Association annual meeting held online, highlighting updates on skin conditions and treatments without reporting new clinical results.
September 2011 in “Chinese Journal of Dermatology” This case report describes a 69-year-old man diagnosed with folliculotropic mycosis fungoides after initially being treated for folliculitis, highlighting emerging skin lesions despite subsequent photochemotherapy and acitretin treatment.
1 citations
,
June 2023 in “International Journal of Scientific Research in Science and Technology” The researchers highlighted the nutritional benefits of kiwifruit, noting its high vitamin C content, dietary fiber, and potassium, as well as its wealth of phytochemicals and antioxidants, which may aid immune function, digestion, and potentially reduce chronic disease risk.
June 2023 in “World Journal of Biology Pharmacy and Health Sciences” This review outlines the complex factors involved in acne pathogenesis—including hormonal, genetic, and environmental influences—and describes current comprehensive management strategies, emphasizing both topical and systemic therapies, while also highlighting emerging treatment options and the significant psychological impact of acne.
3 citations
,
October 2025 in “Biomedicines” This review of seborrheic dermatitis highlights the role of complex immunoinflammatory processes in its pathogenesis and discusses emerging treatments, such as PDE4 inhibitors, JAK inhibitors, and microbiome-targeted therapies, which may benefit patients with severe or treatment-resistant forms, according to the authors.
1 citations
,
December 2022 in “Life” This review systematically analyzed evidence on treatment options for erosive pustular dermatosis, finding that while potent topical steroids like clobetasol propionate can be effective, recurrence is common, and more robust studies are necessary for stronger recommendations.
January 2022 in “Clinical Cases in Dermatology” This article reviews the causes, characteristics, and treatment options for seborrheic dermatitis, discussing its prevalence in specific populations, without providing new research findings.
July 2024 in “Journal of Investigative Dermatology” Brepocitinib reduces interferon signaling in hidradenitis suppurativa patients.
July 2022 in “The journal of investigative dermatology/Journal of investigative dermatology” This study suggests that impaired Nrf2 signaling and its relationship with keratin 16 may contribute to follicular hyperkeratinization and occlusion in hidradenitis suppurativa, opening new therapeutic avenues.
4 citations
,
January 2021 in “PubMed” This review discusses the pathogenesis and management of hidradenitis suppurativa, examining conventional treatments and exploring botulinum toxin type A as a potential therapeutic option, but it reports no new clinical results.
36 citations
,
January 2023 in “Skin Appendage Disorders” This review discusses the etiology, pathophysiology, trichoscopic characteristics, differential diagnoses, and treatment options for scalp seborrheic dermatitis, without providing new clinical findings.
March 2026 in “Biomedicines” This review synthesizes current evidence on therapies for dissecting cellulitis of the scalp, noting that biologics show promise for treatment-resistant cases, though systemic retinoids remain the first-line therapy.
10 citations
,
April 2023 in “JAAD Case Reports” This article discusses the challenges in treating hidradenitis suppurativa, highlighting that adalimumab is currently the only FDA-approved treatment, and reports no clinical results.
July 2023 in “The Egyptian Journal of Hospital Medicine ” This review discusses the pathophysiology of alopecia areata, highlighting the role of CD8 cytotoxic T cells and the upregulation of JAK signaling pathways; it reports no new experimental results.